Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 May;45(3):326-336.
doi: 10.4093/dmj.2020.0272. Epub 2021 Apr 19.

Lobeglitazone: A Novel Thiazolidinedione for the Management of Type 2 Diabetes Mellitus

Jaehyun Bae #  1 , Taegyun Park #  2 , Hyeyoung Kim  3 , Minyoung Lee  4 , Bong-Soo Cha  4
Affiliations
Review

Lobeglitazone: A Novel Thiazolidinedione for the Management of Type 2 Diabetes Mellitus

Jaehyun Bae et al. Diabetes Metab J. 2021 May.

Abstract

Type 2 diabetes mellitus (T2DM) is characterized by insulin resistance and β-cell dysfunction. Among available oral antidiabetic agents, only the thiazolidinediones (TZDs) primarily target insulin resistance. TZDs improve insulin sensitivity by activating peroxisome proliferator-activated receptor γ. Rosiglitazone and pioglitazone have been used widely for T2DM treatment due to their potent glycemic efficacy and low risk of hypoglycemia. However, their use has decreased because of side effects and safety issues, such as cardiovascular concerns and bladder cancer. Lobeglitazone (Chong Kun Dang Pharmaceutical Corporation), a novel TZD, was developed to meet the demands for an effective and safe TZD. Lobeglitazone shows similar glycemic efficacy to pioglitazone, with a lower effective dose, and favorable safety results. It also showed pleiotropic effects in preclinical and clinical studies. In this article, we summarize the pharmacologic, pharmacokinetic, and clinical characteristics of lobeglitazone.

Keywords: Diabetes mellitus, type 2; Lobeglitazone; Thiazolidinediones.

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST

The authors report no potential conflict of interest relevant to this article. Laboratory data analysis and calibration support was provided by Chong Kun Dang Pharmaceutical Corporation, Seoul, Korea.

Figures

Fig. 1.
Fig. 1.
Indirect comparison of glycemic efficacy between lobeglitazone and pioglitazone in patients with type 2 diabetes mellitus based on previous prospective randomized, controlled studies. (A) Monotherapy, short-term, (B) monotherapy, longterm, and (C) add-on to metformin monotherapy. HbA1c, glycosylated hemoglobin.
None
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia. 2003;46:3–19. - PubMed
    1. Lebovitz HE. Thiazolidinediones: the forgotten diabetes medications. Curr Diab Rep. 2019;19:151. - PMC - PubMed
    1. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma) J Biol Chem. 1995;270:12953–6. - PubMed
    1. Kohlroser J, Mathai J, Reichheld J, Banner BF, Bonkovsky HL. Hepatotoxicity due to troglitazone: report of two cases and review of adverse events reported to the United States Food and Drug Administration. Am J Gastroenterol. 2000;95:272–6. - PubMed
    1. Hanefeld M, Pfutzner A, Forst T, Lubben G. Glycemic control and treatment failure with pioglitazone versus glibenclamide in type 2 diabetes mellitus: a 42-month, open-label, observational, primary care study. Curr Med Res Opin. 2006;22:1211–5. - PubMed

MeSH terms